Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 271

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 271
---
 an acquisition target.

#### Reasons for the Amendments
The following is a summary of the reasons for the key changes effected by the Charter Proposal:

• Name Change . Changing the post-combination corporate name from “Iris Acquisition Corp” to “Iris Parent Holding Corp.” is desirable to reflect the Business Combination and to more closely align the name of the publicly traded entity with the name of the existing operating business;

• Authorized Share Capital . The pre-closing Iris Certificate of Incorporation (the “Pre-Closing Iris Certificate of Incorporation”) authorizes: (a) 300,000,000 shares of common stock, including 280,000,000 shares of Iris Class A Common Stock and 20,000,000 shares of Class B Common Stock and (b) 1,000,000 shares of preferred stock. This Proposal No. 4 provides that Liminatus will be authorized to issue 501,000,000 shares, consisting of 500,000,000 shares of common stock and 1,000,000 shares of preferred stock. Upon the elimination of the blank check provisions in the Pre-Closing Iris Certificate of Incorporation, the Iris Board determined that there was no longer a need to continue with two (2) series of common stock and that it was desirable to increase the number of shares of authorized common stock. Therefore, this Proposal No. 2 eliminates the Class B Common Stock and increases the number of shares of authorized common stock;

• Dual-Class Capital Structure . The Pre-Closing Iris Certificate of Incorporation contains provisions regarding the conversion of Class B Common Stock and anti-dilution protections in respect of Class B Common Stock. The Pre-Closing Iris Certificate of Incorporation also requires the affirmative vote of the holders of a majority of the shares of Class B Common Stock in order to make any amendment that would

<div align='center'>131</div>

TABLE OF CONTENTS

alter or change the powers, preferences or other rights of the holders of Class B Common Stock. The ParentCo Certificate of Incorporation eliminates Class B Common Stock and any rights of holders thereof. Following the merger, the protections afforded the Class B Common Stock while Iris was a special purpose acquisition company will no longer be necessary. The Iris Board believes that the provisions relating to the Class B Common Stock will no longer be relevant to Liminatus and should be eliminated;

• Amendment . The amendment is intended to protect certain key provisions of the ParentCo Certificate of Incorporation from arbitrary amendment and to prevent a simple majority of stockholders